Foghorn Therapeutics Inc. Retained Earnings
Foghorn Therapeutics Inc. (FHTX) had Retained Earnings of -$659.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$659.53M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$652.34M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$632.47M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$610.80M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$659.53M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$652.34M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$632.47M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$610.80M 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$594.95M 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$577.02M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$558.18M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$538.68M 10-Q · filed 2024-11-04 |
| 2024-06-30 | -$519.56M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$496.58M 10-Q · filed 2024-05-06 |
| 2023-12-31 | -$471.56M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$447.46M 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$433.11M 10-Q · filed 2023-08-04 |
| 2023-03-31 | -$403.63M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$373.14M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$344.25M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$318.48M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$291.17M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$264.26M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$235.11M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$209.03M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$185.92M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$162.94M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | -$142.18M 10-Q · filed 2020-12-04 |
| 2019-12-31 | -$94.14M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |